<DOC>
	<DOCNO>NCT02782351</DOCNO>
	<brief_summary>The present study evaluate safety efficacy humanize Chimeric antigen receptor T cell ( CAR-T ) treat recurrent refractory B cell malignancy target CD19 humanize scFv . All participant receive autologous chimeric antigen receptor engineer T cell .</brief_summary>
	<brief_title>Humanized CAR-T Therapy Treatment B Cell Malignancy</brief_title>
	<detailed_description>CD19 extensively evaluate therapeutic target recurrent refractory B cell malignancy chimeric antigen receptor T cell therapy , single chain antibody sequence ( scFv ) CD19 derive mouse hybridoma widely employ . However , immunogenicity mouse scFv sequence might one reason CAR-T cell persist vivo long . In present study investigator replace mouse-derived scFv humanize one evaluate safety efficacy .</detailed_description>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Ageâ‰¥10 time consent Survival time &gt; 12 week B cell hematological malignancy pathological examination Chemotherapy failure recurrent B cell malignancy Creatinine &lt; 2.5mg/dl Glutamicpyruvic transaminase , glutamic oxalacetic transaminase &lt; 3 fold normal level Karnofsky Performance Status &gt; 50 % time screen Bilirubin &lt; 2.0mg/dl Adequate pulmonary , renal , hepatic , cardiac function Fail autologous allogenic haemopoietic stem cell transplantation Free leukocytes removal contraindication Pregnant nursing woman Active hepatitis B , active hepatitis C , human immunodeficiency virus ( HIV ) infection time screen Previous treatment gene therapy product Abnormal vital sign Highly allergic constitution history severe allergy , especially allergy interleukin2 General infection local severe infection , infection control Dysfunction lung , heart , kidney brain . Severe autoimmune disease symptoms applicable CART</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>